1. The journey of MEFV heterozygous children: with or without colchicine.
- Author
-
Çakan M, Alkaya A, Koru L, Öksel B, Akgün Ö, Tunce E, Yener GO, Tanatar A, Demir F, Şahin N, Bağlan E, Öztürk K, Sönmez HE, Özdel S, Sözeri B, and Ayaz NA
- Subjects
- Humans, Female, Male, Child, Retrospective Studies, Child, Preschool, Adolescent, Infant, Genetic Testing, Follow-Up Studies, Tubulin Modulators therapeutic use, Colchicine therapeutic use, Familial Mediterranean Fever genetics, Familial Mediterranean Fever drug therapy, Familial Mediterranean Fever diagnosis, Pyrin genetics, Heterozygote
- Abstract
To investigate the rate of colchicine use in the longitudinal follow-up of familial Mediterranean fever (FMF) carriers and identify variables that could predict the necessity of colchicine treatment in this group. The study was conducted in 9 pediatric rheumatology centers. The files of children with MEFV gene carriers were retrospectively reviewed between February 2014 and May 2024. The study included 869 children with a median follow-up duration of 28 months (12-124). In most of the cases (n: 369; 43.5%), MEFV gene analysis was ordered by a pediatric rheumatologist, while in 228 children (26.2%), gene analysis was conducted at the request of a geneticist. The most common reason for ordering MEFV gene analysis was the presence of FMF-like symptoms (n: 349; 40.1%), followed by genetic screening due to a family history of FMF in relatives (n: 267; 30.7%). Colchicine therapy was initiated in 13.9% (n: 121) of the children. Variables that showed statistically significant differences in colchicine users included having a family history of amyloidosis, the MEFV gene ordered by a pediatric rheumatologist, and the presence of FMF-like symptoms. Conclusions: A small number of MEFV gene carriers develop FMF symptoms during the follow-up period, most commonly within 2-3 years. We do not recommend routine family screening for the MEFV gene after the diagnosis of an index patient unless there is a history of amyloidosis in the family or individuals having FMF-like symptoms., Competing Interests: Declarations. Ethics approval: The study was approved by the local ethics committee of Zeynep Kamil Women and Children’s Diseases Training and Research Hospital (date: 20 March 2024, number: 38) and was performed according to the tenets of the Declaration of Helsinki. Written informed consent was received from the legal guardians of the children. Consent to participate: Informed consent was obtained from the legal guardians of the children. Consent for publication: Informed consent for publication was obtained from the legal guardians of the children. Competing interests: The authors declare no competing interests., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF